Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD
Source: SeekingAlpha
2025-03-27 20:31:43 ET
More on Clearside Biomedical
- Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript
- Clearside Biomedical GAAP EPS of -$0.10 in-line, revenue of $0.3M beats by $0.01M
- Seeking Alpha’s Quant Rating on Clearside Biomedical
- Historical earnings data for Clearside Biomedical
- Financial information for Clearside Biomedical
Read the full article on Seeking Alpha
For further details see:
Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD
Clearside Biomedical Inc.
NASDAQ: CLSD
CLSD Trading
-90.6% G/L:
$0.41 Last:
1,945,057 Volume:
$0.57 Open:
CLSD Latest News
November 24, 2025 07:05:00 am
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
CLSD Stock Data
$3,521,323
4,883,304
0.23%
26
757199%
Biotechnology & Life Sciences
Healthcare
US
Alpharetta
